Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04213963
Other study ID # The PrePARe Study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2011
Est. completion date October 31, 2025

Study information

Verified date November 2020
Source University of Turin, Italy
Contact Mauro M Maccario, MD
Phone 00390116709559
Email mauro.maccario@unito.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prevalence of primary aldosteronism (PA) in resistant hypertension is not clear. In addition, emerging evidence supports the role of elevated serum aldosterone in promoting cardiovascular disease, independently from high blood pressure (BP) levels, but current data on this issue are heterogeneous.


Description:

PA is the most frequent form of secondary hypertension, with a prevalence that increases with the severity of hypertension. The wide variation of the reported PA prevalence is due to different study design and population. Very few data derive from well designed prospective study. Additional problems in the interpretation of study results are the different diagnostic cut-off used in various centers and the low diffusion of the adrenal vein sampling, that has a central role in the PA diagnosis. Resistant hypertension (RH) is a condition of insufficient BP control, despite appropriate lifestyle measures and treatment with at least 3 drugs at full dose, including a diuretic, in patients whose adherence to therapy has been confirmed. The primary aim of our study is define prospectively the prevalence of PA in RH. Moreover, emerging evidence supports the crucial role of elevated serum aldosterone in promoting cardiovascular disease, independently from high BP levels. Aldosterone improves oxidative stress, inflammation, impairs insulin metabolic signaling, reduced endothelial-mediated vasorelaxation and is associated to cardiovascular and renal abnormalities. However, current data on the contribution of PA on cardiometabolic complications have heterogeneous results. The secondary outcome of our study is to investigate prospectively the association of PA with cardiometabolic complications in a cohort of patients with RH.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 31, 2025
Est. primary completion date September 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - age over 18 and under 80 years old; - diagnosis of resistant hypertension defined as: uncontrolled blood pressure at ambulatory blood pressure measurement (ABPM), despite the use of at least 3 antihypertensive drugs at full dose, including a diuretic. Exclusion Criteria: - age under 18 or over 80 years old; - pseudo-resistant hypertension (poor medication adherence, high salt intake); - previous cardiovascular disease; - insulin treated diabetes mellitus; - other than primary aldosteronism cause of secondary hypertension (obstructive sleep apnea, renal artery stenosis, pheochromocytoma/paraganglioma, primary hyperparathyroidism, autonomous cortisol secretion or over hypercortisolism); - liver cirrhosis; - chronic heart failure; - known malignant neoplasm; - chronic disease with major organ involvement; - excessive alcohol ingestion; - current steroids assumption; - use of sympathomimetic drugs; - use of contraceptives.

Study Design


Locations

Country Name City State
Italy Division of Endocrinology, Diabetology and Metabolism; University of Turin Torino Piemonte

Sponsors (1)

Lead Sponsor Collaborator
University of Turin, Italy

Country where clinical trial is conducted

Italy, 

References & Publications (24)

Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec;40(6):892-6. — View Citation

Chandran P. Resistant or difficult-to-control hypertension. N Engl J Med. 2006 Nov 2;355(18):1934; author reply 1934. — View Citation

Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008 Jun 7;371(9628):1921 — View Citation

Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004 Nov;22(11):2217-26. — View Citation

Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007 Aug;20(8):855-61. — View Citation

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006 Feb;91(2):454-9. Epub 2005 Nov 15. — View Citation

Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev. 2005 Jan;10(1):47-52. Review. — View Citation

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 Ma — View Citation

Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005 Apr;16(3):120-6. Review. — View Citation

Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, De Toma G, Sciomer S, Letizia C. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010 May;95(5):2391-8. doi: 10.1210/jc.2009-2204. Ep — View Citation

Lucatello B, Benso A, Tabaro I, Capello E, Caprino MP, Marafetti L, Rossato D, Oleandri SE, Ghigo E, Maccario M. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion. Eur J — View Citation

Marzano L, Colussi G, Sechi LA, Catena C. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am J Hypertens. 2015 Mar;28(3):312-8. doi: 10.1093/ajh/hpu154 — View Citation

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol — View Citation

Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86. Epub 2004 Dec 9. Review. — View Citation

Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004 — View Citation

Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med. 1999 Dec;27(11-12):1173-81. Review. — View Citation

Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, M — View Citation

Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Muiesan ML, Mannelli M, Negro A, Palumbo G, Parenti G, Rossi E, Mantero F; PAPY Study Investigators. Adrenalectomy Lowers Incident A — View Citation

Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008 Apr;19(3):88-90. doi: 10.1016/j.tem.2008.01.006. Epub 2008 Mar 7. Review. — View Citation

Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003 Jan;16(1):80-6. Review. — View Citation

Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003 May;17(5):349-52. — View Citation

Vassalle C, Pratali L, Boni C, Mercuri A, Ndreu R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin Biochem. 2008 Oct;41(14-15):1162-7. doi: 10.1016/j.clinbioch — View Citation

Vogt B, Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep. 2009 Dec;11(6):450-5. Review. — View Citation

Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004. Review. — View Citation

* Note: There are 24 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Number of diagnosis (prevalence) of primary aldosteronism in prospective cohort of patients with resistant hypertension. Basal Aldosterone (pg/mL) at baseline. Baseline.
Primary Number of diagnosis (prevalence) of primary aldosteronism in prospective cohort of patients with resistant hypertension. Basal Plasma Renin Activity (PRA, ng/mL/h) at baseline. Baseline.
Primary Number of diagnosis (prevalence) of primary aldosteronism in prospective cohort of patients with resistant hypertension. Aldosterone (pg/mL) post saline infusion test, performed at baseline. Baseline.
Secondary Left ventricular hypertrophy in primary aldosteronism and essential resistant hypertension Left ventricular mass evaluation with Echocardiogram at baseline. Baseline.
Secondary Microalbuminuria in primary aldosteronism and essential resistant hypertension. Albuminuria/Creatininuria ratio (mg/mmoL) at baseline. Baseline.
Secondary Intima media thickness > 0.9 mm rate in primary aldosteronism versus essential resistant hypertension. Intima media thickness values (mm) evaluation with carotid Doppler ultrasound at baseline. Baseline
Secondary Chronic kidney disease in primary aldosteronism versus essential resistant hypertension. Serum creatinine (mg/dL) at baseline. Baseline.
Secondary Aortic ectasia in primary aldosteronism versus essential resistant hypertension. Aortic size (mm) determined with echocardiogram at baseline. Baseline.
Secondary Atrial fibrillation in primary aldosteronism versus essential resistant hypertension. Electrocardiogram (ECG) at baseline. Baseline.
Secondary Insulin resistance in primary aldosteronism versus essential resistant hypertension. Oral glucose tolerance test (OGTT) for determination of glucose (mg/dL) at time 0', 30', 60', 90' and 120' at baseline. Baseline
Secondary Insulin resistance in primary aldosteronism versus essential resistant hypertension. Oral glucose tolerance test (OGTT) for determination of insulin (mg/dL) at time 0', 30', 60', 90' and 120' at baseline. Baseline.
Secondary Diabetes mellitus rate in primary aldosteronism versus essential resistant hypertension. Oral glucose tolerance test (OGTT) for determination of glucose (mg/dL) at time 0' and 120' at baseline. Baseline.
Secondary Diabetes mellitus rate in primary aldosteronism versus essential resistant hypertension. HbA1c (mmol/mol) at baseline. Baseline.
Secondary Sodium levels in primary aldosteronism versus essential resistant hypertension. Serum Sodium (mmol/L) at baseline. Baseline.
Secondary Potassium levels in primary aldosteronism versus essential resistant hypertension. Serum Potassium (mmol/L) at baseline. Baseline.
Secondary Oxidative stress in primary aldosteronism versus essential resistant hypertension. Blood determination of 8-isoprostane (UI/L) at baseline. Baseline.
Secondary Oxidative stress in primary aldosteronism versus essential resistant hypertension. Blood determination of total antioxidant capacity (UI/L) at baseline. Baseline.
Secondary Dyslipidemia in primary aldosteronism versus essential resistant hypertension. Serum triglycerides (mg/dL) at baseline. Baseline.
Secondary Dyslipidemia in primary aldosteronism versus essential resistant hypertension. Serum total-Cholesterol (mg/dL) at baseline. Baseline.
Secondary Dyslipidemia in primary aldosteronism versus essential resistant hypertension. Serum HDL-Cholesterol (mg/dL) at baseline. Baseline.
Secondary Dyslipidemia in primary aldosteronism versus essential resistant hypertension. Serum LDL-Cholesterol (mg/dL) at baseline. Baseline.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A